Earlier quoted context omitted.
I'm not fully convinced here, I bet those long term patients were on antipsychotics nearly all of which have extrapyramidal side effects, pretty identical to negative symptoms.
It’s worth mentioning here that antipsychotics have come a long way since lithium. (Posting from the US with our unfortunate (relative to the developed world) healthcare system.) There’s a handful of antipsychotics and mood stabilizers that have been developed in the last couple of decades that have had unprecedented success with Schizophrenia and Bipolar Disorder. They typically cost $20,000.00 per year before insur…
Haha it did make me wander if there was an Emacs HN client with paren mode.
> It’s worth mentioning here that antipsychotics have come a long way since lithium.
It's not really related to your comment which is interesting and useful to hear in of its self.
But Lithium is not a antipsychotic it's a mood stabiliser and remains to this day a good one. It remains to this day the best evidenced for suicide reduction and intractable depression.
Mood stabilizers haven't progressed much (valproate a favoured one is now out for fertile women due to risk of ASD and birth defects).
Antipsychotics have shown astounding progress as you say, the reintroduction of clozapine in the 90, introduction of second generations, then Aripiprazole(as a partial D2 agonist was a warning shot we didn't know as much as we thought), quetiapine (made us reassess what a second generation even means as it has even less D2 affinity), pimavanserin (! No D2 but some 5HT-2a activity) And future like SEP-856(!! What the fuck is TAAR1?!).
Represent astounding progress. Should SEP-856 get a market authorization it'll turn decades of the dopamine hypothesis fully on its head.